Hyperkalemia is a predictable, treatable, and manageable condition, according to Aaron Wong. He shares his practical experience to manage the risk of hyperkalemia using a novel potassium binder, which allows for the optimization of RAASi therapy in HF.
In a prespecified analysis of the STEP-HFpEF trial among patients with the obesity phenotype of HFpEF, semaglutide reduced body weight and HF-related symptoms and signs compared with placebo across all 3 obesity categories.
ESC Congress 2023 How do healthy lifestyle interventions fit in the current therapeutic landscape for patients with established CVD? Nadia Bonekamp interviews Ruxandra Maria Christodorescu about this topic.
What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.
ESC Congress 2023 A post-hoc analysis of FIDELITY showed that baseline anemia status modifies the effect of finerenone on cardiovascular outcomes, but not renal outcomes, in patients with CKD and T2D.
ESC Congress 2023 Kausik Ray summarizes the findings of a pre-specified analysis of the CLEAR Outcomes trial in which the efficacy and safety of bempedoic acid was examined in patients with normoglycemia, prediabetes and diabetes.
ESC Congress 2023 Nikolaus Marx presents the main messages of the 2023 ESC Guidelines for the management of CVD in patients with diabetes.
ESC Congress 2023 A prespecified analysis of the CLEAR Outcomes trial investigated whether trial data of bempedoic acid are concordant with genetic data for ACLY inhibition with regard to CV risk reduction, glycemia and risk of new onset diabetes.
ESC Congress 2023 The STEP HFpEF trial shows that semaglutide improves HF-related symptoms and leads to greater weight loss in patients with HFpEF. “Collectively, these findings indicate that semaglutide is a valuable treatment option in patients with HFpEF and obesity” says Mikhail Kosiborod.
ESC Congress 2023 STEP HFpEF showed that once-weekly semaglutide 2.4 mg improved HF-related symptoms, physical limitations and exercise function, and led to greater weight loss in patients with HFpEF and obesity, compared with placebo.
In the SELECT trial, treatment with the GLP-1RA semaglutide reduced the risk of MACE in adults with overweight or obesity and established CVD.
A population-based cohort study showed that loneliness, but not social isolation, was associated with a higher CVD risk in patients with DM. Loneliness also ranked higher in relative strength for predicting CVD risk than lifestyle risk factors such as smoking and diet.